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Abstract
Aeromonas sobria infection often advances to sepsis, in which interaction of
bacterial components with plasma proteins possibly causes various disorders. This
bacterium releasesa serine protease (ASP), a putative virulencefactor, and binds to
ﬁbrinogen. To study the ASP effect on ﬁbrinogen, we incubated ﬁbrinogen or
plasma with ASP and investigated their clotting elicited by thrombin, which
converts ﬁbrinogen to a ﬁbrin clot. Enzymatically active ASP retarded plasma
clotting in a dose-dependent manner starting at an ASP concentration of 10nM.
ASP also retarded ﬁbrinogen clotting at 3nM and above, which appeared to
correspond to ASP cleavage of ﬁbrinogen at the Aa-chain. Consistent with
containing serine protease activity for an ASP-speciﬁc substrate, the culture
supernatant of an ASP gene-introduced strain retarded plasma and ﬁbrinogen
clotting more than that of the wild-type strain. The culture supernatant of an ASP
gene-disrupted strain that releases negligible serine protease activity for the ASP-
speciﬁc substrate did not affect plasma clotting. These results indicate that ASP is
the main ﬁbrinogenolytic protease released from A. sobria. Impaired plasma
clottability induction through ﬁbrinogen degradation is a new virulence activity
of ASPand maycontribute to hemorrhagic tendencies in sepsis caused by infection
with this bacterium.
Introduction
Aeromonas species are facultative anaerobic Gram-negative
rods that are widely distributed in aquatic environments
(Jones & Wilcox, 1995) and commonly implicated as
causative agents of gastroenteritis (Janda & Brenden, 1987;
Janda & Abbott, 1998). Aeromonas infections, either
through wounds or via the digestive tract, often develop
into sepsis, particularly in immunocompromised individuals
(Janda & Abbott, 1998). Aeromonas hydrophila, Aeromonas
sobria,a n dAeromonas caviae are three major Aeromonas
subspecies, and A. sobria, frequently isolated from patients’
blood (Janda et al., 1984), is markedly more virulent than
other Aeromonas species (Janda & Brenden, 1987).
Aeromonas species release several putative virulence fac-
tors, including hemolysins, enterotoxins, and proteases
(Janda, 1991). As a putative virulence factor, we puriﬁed a
65-kDa serine protease, referred to as Aeromonas serine
protease (ASP), from the culture supernatant of A. sobria
(Yokoyama et al., 2002). ASP is a member of the kexin
familyof subtilisin-likeproteases(Siezen & Leunissen, 1997)
and preferentially cleaves peptide bonds at the carboxy-
terminal side of paired basic residues (Kobayashi et al.,
2006). Recently, we found that ASP caused vascular leakage
and lowered blood pressure by cleaving components of the
plasma kallikrein/kinin system (Imamura et al., 2006),
suggesting a contribution of ASP to septic shock in A. sobria
infections. Thus, interaction of ASP with plasma proteins
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disease caused by this pathogen, especially in sepsis.
Fibrinogen, a plasma protein, is converted to a ﬁbrin clot
by thrombin, protecting the host from blood loss by bleed-
ing (Mann & Lundblad, 1987). Degradation of ﬁbrinogen
and ﬁbrin leads to loss of plasma clottability and rebleeding,
respectively, causing hemorrhagic tendencies that are a
prominent symptom in disseminated intravascular coagula-
tion (DIC), a common and potentially deadly complication
in sepsis patients (Levi, 2001). The ability of Aeromonas
species to bind ﬁbrinogen (Ascencio et al., 1990) suggests
thatASPreleased fromA. sobria maydegrade ﬁbrinogen and
abrogate plasma clottability. To examine this virulence
activity, we investigated the ﬁbrinogenolytic activity of ASP,
and to study the contribution of ASP to ﬁbrinogen degrada-
tion by A. sobria, we measured the ﬁbrinogenolytic activity
of the culture supernatants from an ASP gene-disrupted
or -introduced strain.
Materials and methods
Materials
Human ﬁbrinogen and bovine thrombin were purchased
from Sigma-Aldrich Corp. (St. Louis, MO), and t-butyloxy
carbonyl–L-glutamyl–L-lysyl–L-lysine–4-methylcoumaryl-
7-amide (Boc–Glu–Lys–Lys–MCA) was obtained from the
Peptide Institute (Minoh, Japan). Other chemicals were
purchased from Wako Pure Chemical Industries (Osaka,
Japan). Normal human plasma was prepared by centrifu-
gation of a mixture of 9vol of freshly drawn blood from
healthy volunteers and 1vol of 3.8% (w/v) sodium citrate.
The bacterial strains, plasmids, and their sources used in
this study are listed in Table 1. Both Eschrichia coli and
A. sobria were grown at 371Ci nL u r i a – B e r t a n i( L B )b r o t h
and agar plates. A wild-type strain 288 was isolated
clinically (Fujii et al., 1998).
Preparation of asp -disrupted or -introduced
strain
Fragments of strain 288 chromosomal DNA digested with
the EcoRI were inserted into the EcoRI site of pUC119
(Okamoto et al., 2000) and introduced into E. coli HB101
(TaKaRa Co., Kyoto, Japan). Protease-positive clones were
selected using the LB agar medium containing 3% skim milk
(Nakarai Co., Kyoto, Japan). Sequence analysis of the cloned
insert DNA (5528bp) in pUC119-5528 (Nomura et al.,
2002) identiﬁed an operon composed of two structural
genes, asp and orf2, which codes for a speciﬁc chaperone
required for ASP maturation (GenBank accession no.
AF253471).
Disruption of asp and orf2 was carried out according to
the homologous recombination technique (Kuroda et al.,
2005) using a suicide vector pXAC623 (Nishibuchi et al.,
1991; Schweizer & Hoang, 1995). To cleave off the regions
from 1766 to 3408, pUC119-5528 was digested with NcoI
and BglII and treated with Klenow fragment (TaKaRa Co.).
The defective gene fragment was circularized by T4 DNA
ligase (TaKaRa Co.) [pUC119-5528 (Dasp)] (Khan et al.,
Table 1. Strains and plasmids
Properties Sources or references
Strains
A. sobria strains
288 Wild-type strain producing ASP and metalloprotease Fujii et al. (1998)
288 (Dasp) 288 strain disrupted both asp and orf2 Khan et al. (2007)
T94 Atypical strain not producing ASP and metalloprotease Khan et al. (2007)
E. coli
HB101 Cloning host, supE44, D(mcrC-mrr), recA13, ara-14, proA2, lacY1, galK2,
rpsL20, xyl-5, mtl-1, leuB6, thi-1
TaKaRa Co.
SY327lpir D(lac-pro) argE(Am) recA56 nalA Rf
r (lpir) Nishibuchi et al. (1991)
SM10lpir Thi-1 thr leu tonA lacy supE recA::RP4-2Tc::Mu lpir R6K, Km
r Nishibuchi et al. (1991)
Plasmids
Cloning vectors
pUC119 General cloning vector, Ap
r TaKaRa Co.
pSA19CP Shuttle vector replicable in E. coli and Aeromonas,C m
r Nomura et al. (2002)
pXAC623 Suicide vector, Cm
r, pEX100Tand pKTN701 derivative with R6K ori and mob RP4 Schweizer & Hoang (1995),
Nishibuchi et al. (1991)
Constructed plasmids
pUC119-5528 pUC119 derivative carrying 5528-bp gene fragment containing asp and orf2 Okamoto et al. (2000)
pUC119-5528 (Dasp) pUC119-5528 defect of the gene fragment from 1776 to 3408nt Khan et al. (2007)
pXAC-5528 (Dasp) pXAC623 derivative defect of the gene fragment from 1776 to 3408nt in
5528-bp gene fragment
Khan et al. (2007)
PSA19-5528 pSA19CP derivative carrying 5528-bp gene fragment containing asp and orf2 Okamoto et al. (2000)
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36 T. Imamura et al.2007) and ampliﬁed by PCR (2min at 941C, followed by
25 cycles of 10s at 981C, 30s at 501C, and 5min at 721C)
using two primers: 50-TTTCGTTCTAGAGCCGGGC-
CACGTTCA-30 and 50-CGACCCTCTAGAGGGGGCGCCC
GGCGG-30. These primers cover the upstream and down-
stream regions of the defective gene, respectively, and
contain a XbaI site (underlined). The ampliﬁed gene frag-
ment was digested using XbaI and inserted into a unique
XbaI site of the suicide vector pXAC623. The plasmid,
designated as pXAC-5528 (Dasp) (Fig. 1a), was introduced
into E. coli SM10lpir. The SM10lpir was cultured with
strain 288 until the exponential phase and was harvested on
a membrane ﬁlter (0.2-mm pore size, Advantec Co., Tokyo,
Japan) by ﬁltration. This membrane was placed on an
LB-broth agar plate and incubated at 371C for 3h to deliver
pXAC-5528 (Dasp) from SM10lpir to strain 288 by con-
jugation. The bacterial cells on the membrane were resus-
pended in LB broth and cultured at 371C for 1h. The
ﬁrst homologous recombination produced a 288 strain
possessing both the wild and defective asp-orf2 genes, and
CATand sacB genes from the pXAC623 vector (Fig. 1a). The
cell suspension spread onto an LB-broth agar plate contain-
ing 5mgmL
 1 chloramphenicol and 50mgmL
 1 ampicillin
was incubated at 301C overnight. Only the recombinant
strain with the CAT gene grew, and was cultured in LB broth
without antibiotics. During this procedure, the second
homologous recombination occurred between the full-
length and the defective asp-orf2 genes (Fig. 1a). To exclude
the strain that did not have the second recombination,
therefore retaining the sacB gene, the bacterial culture
spread onto an LB-broth agar plate containing 10% sucrose
was incubated at 251C. The asp-orf2-disrupted 288 strain
created, designated as 288 (Dasp), was conﬁrmed by South-
ern-hybridization analysis (Fig. 1b, lane 4).
To prepare a high ASP secretion strain, strain T94 was
introduced with pSA19-5528 containing asp-orf2 and CAT
genes (T94/pSA19-5528), and selected using LB-broth agar
plates containing 5mgmL
 1 chloramphenicol. Strain T94
introduced the vector alone (T94/pSA19CP) was used as a
control.
Chromosomal asp   operon gene of  A. sobria 288 
1436 1766  3408  3784 
asp orf2 
The first recombination
The second recombination
asp orf2 
defective  asp-orf2 
pXAC-5528 
CAT
sacB
ori R6K 
CAT sacB ori R6K 
asp orf2 
A. sobria 288 (∆asp)  
(∆asp)  
(a)
(b) (c) Eco RI 
A. sobria 288 (∆asp)   
Eco RI 
Eco RI  Eco RI 
Probe 
asp orf2 
5528 bp 
3889 bp  Probe 
Probe 
Wild type 
Lane    1  2  3 4 
digested Eco  RI 
kDa    1                  2                 3 
250 
150 
100 
75 
50 
37 
25 
Fig. 1. (a) Disruption of asp-orf2 using suicide
vector pXAC-5528 (Dasp). The ﬁrst homologous
recombination produced a mutant 288
possessing asp-orf2 and the defective gene on
pXAC-5528 (Dasp), and CATand sacB genes.
The second homologous recombination
occurred between both types of genes located
in tandem and produced the asp-orf2-disrupted
strain. (b) Southern-hybridization analysis of
asp-orf2.T h easp-orf2 detection DNA probe
(b, horizontal bar) that had EcoRI digestion sites
at both sides was ampliﬁed using two primers
AP-20 (50-CATCGGCGGCAACCGCGGAA-30)
and AP-25 (50-ATGCCGCTCTCCTTGCCGGT-30),
and labeled digoxigenin DNA Labeling Kit. Total
DNAs extracted from both 288 (lanes 1 and 3)
and 288 (Dasp) (lanes 2 and 4) using Qiagen
Genomic-tips were digested with EcoRI and
separated on 0.7% agarose gel. Southern-
hybridization reaction with the digoxigenin-
labeled probe was performed and hybridized
fragments were detected with the digoxigenin
luminescent detection kit. Numbers along the
left side indicate DNA sizes in base pairs (bp).
(C) SDS-PAGE of ASP. ASP (0.6mg) was analyzed
using a SDS-polyacrylamide gel (10%) in the
presence (lane 3) or absence of 2-ME (lane 2),
and the gel was silver-stained. Lane 1, molecular
size markers.
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Two hundred microliters of the culture of a strain at the
stationary phase was added to 100mL of LB-broth medium.
The medium was incubated at 371C with shaking
(160r.p.m.) and 100mL of the culture sample was taken
every 3h. The sample was serially diluted, plated onto LB-
agar plates, and cultured for bacterial colony count.
Measurement of the protease activity of culture
supernatants
The bacterial cell culture supernatant, after a 12-h incuba-
tion at 371C was centrifuged at 12000g for 15min. The
culture supernatant (35mL) treated with or without a serine
protease inhibitor di-isopropyl ﬂuorophosphate (DFP)
(ﬁnal 1mM) was added to 65mL of 1% azocasein in 10mM
Tris-HCl buffer (pH 7.5) and incubated at 371C for 1h,
followed by addition of 100mL of 10% trichloroacetic acid.
After centrifugation at 13000g, 100mL of the supernatant
was mixed with an equal volume of 1N NaOH and the
A450nm was measured. The culture supernatant (133mL)
treated with or without DFP (ﬁnal 1mM) was added to
12mL of 1.1mM Boc–Glu–Lys–Lys–MCA in 11mM sodium
phosphate buffer (pH 7.5) and incubated at 371C for
30min, followed by addition 150mL of acetic acid
(130mM). The AMC released was measured ﬂuorophoto-
metrically at lex=380nm and lem=440nm using a ﬂuor-
escence spectrophotometer (Model 650-40, Hitachi Co.,
Japan).
Purification of ASP
ASP was puriﬁed from the culture supernatant of T94/
pSA19-5528 (Okamoto et al., 2000) by successive column
chromatography. The ASP sample was analyzed by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) (10% polyacrylamide gel) and found to be
homogenous, showing a single band under reducing and
nonreducing conditions, with a molecular mass of 65kDa
(Fig. 1c). To abolish enzymatic activity, ASP and culture
supernatants were treated with 1mM DFP and dialyzed
against 10mM Tris–HCl (pH 7.3) containing 150mM
NaCl (TBS).
Thrombin time (TT) assay
Conversion of ﬁbrinogen to ﬁbrin by thrombin leads to
clotting; thus, ﬁbrinogen degradation results in impaired
clotting. To examine the ﬁbrinogenolytic activity of ASP, the
thrombin-induced clotting time prolongation of ﬁbrinogen
or plasma incubated with ASP was measured with KC4
(Trinity Biotech, Bray, Ireland). For the TTassay, 67.5mLo f
citrated human plasma or ﬁbrinogen (3mgmL
 1) was
incubated with 7.5mL of ASP in a plastic cell at 371C for
3min, followed by addition of 75mL of bovine thrombin
(5UmL
 1) to initiate clotting. As a control, TBS, used for
ASP dilution, was added instead of ASP.
SDS-PAGE
ASP (15mL, 300nM) was incubated with 135mL of human
ﬁbrinogen (3mgmL
 1 in 50mM Tris–HCl, pH 7.4, contain-
ing 0.1M NaCl) at 371C. At various time periods, 15mLo f
the mixture was withdrawn, followed by the addition of 1mL
of DFP (10mM) to terminate the reaction. Samples were
analyzed by SDS-PAGE under reducing conditions using a
10% polyacrylamide gel. Coomassie Brilliant Blue R-250
was used for protein staining.
Results
Reduction of fibrinogen and plasma clottability
by ASP
To determine whether ASP could affect ﬁbrinogen clottabil-
ity, we measured TTafter incubating ASP with this clotting
factor at the normal plasma concentration (3mgmL
 1)
(Halkier, 1991). ASP prolonged the ﬁbrinogen TT in a
dose-dependent manner, starting at an ASP concentration
of 3nM (Fig. 2a). To examine the ASP effect on ﬁbrinogen
under semi-physiological conditions, we measured TTafter
incubating plasma with ASP. ASP prolonged plasma TT in a
dose-dependent manner, starting at an ASP concentration
of 10nM (Fig. 2b), indicating that ASP can reduce the
clottability of ﬁbrinogen in plasma. Because DFP-inacti-
vated ASP did not affect TT (Fig. 2a and b), the TT
prolongation effect of ASP occurred through its proteolytic
cleavage of ﬁbrinogen. Because ASP did not activate plasmi-
nogen (data not shown), the involvement of plasmin-
mediated ﬁbrinogen degradation in this ASP prolongation
effect on thrombin-induced plasma clotting is unlikely. That
the clottability reduction of plasma required more ASP than
that of ﬁbrinogen (Fig. 2a and b) suggests interference of
plasma proteins, including possibly protease inhibitors, in
the reaction. Overall, these results indicated that ASP
impaired plasma clottability through ﬁbrinogen cleavage.
Cleavage of human fibrinogen by ASP
To study the mechanism of the ﬁbrinogen clottability
reduction by ASP, ﬁbrinogen was analyzed by SDS-PAGE
after incubation with the protease (Fig. 3). ASP degraded
ﬁbrinogen in an incubation time-dependent manner and
the Aa-chain (66kDa) disappeared completely at 2min,
followed by Bb-chain (54kDa) degradation. Because no
clear band, except for the Bb- and g-chains, was seen after
the Aa-chain disappeared, it seems likely that the Aa-chain
was quickly degraded to small peptides. The decrease in the
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38 T. Imamura et al.Bb-chain was coincident with an increase in a band with a
molecular weight similar to that of the g-chain and the
appearance of bands smaller than the g-chain.
Effect of the culture supernatants of the ASP
gene-disrupted or -inserted strain on fibrinogen
clottability
To investigate the role of ASP in ﬁbrinogen degradation by
A. sobria, the culture supernatants of the asp-disrupted or
the asp-introducedstrains were examined for theireffects on
TT. The asp-disrupted strain and the wild-type strain grew
at almost the same rate, and growth of the T94 strains
introduced pSA19-5528 or the vector was slightly lower
(Fig. 4, inset). To conﬁrm the effect of asp gene modiﬁca-
tion, we measured the protease activity of culture super-
natants using substrates Boc–Glu–Lys–Lys–MCA highly
speciﬁc for ASP (Kobayashi et al., 2006), and azocasein for
a broad range of speciﬁcities. The supernatant of the asp-
disrupted strain contained negligible DFP-sensitive protease
activity for both substrates, whereas DFP-sensitive protease
activity in the supernatant of the asp-introduced strain was
about fourfold higher than that in the supernatant of the
wild strain (Fig. 4). DFP inactivated most of the supernatant
protease activity of the wild strain for both substrates and of
the asp-introduced strain for Boc–Glu–Lys–Lys–MCA, but
these supernatants, except for the wild strain supernatant,
contained DFP-resistant azocaseinolytic activity at similar
levels (Fig. 4). These results indicated that ASP accounted
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39 Fibrinogen degradation by Aeromonas serine proteasefor almost all of the serine protease activity released fromthe
wild strain and was absent in the culture supernatant of the
asp-disrupted strain.
The culture supernatants prolonged ﬁbrinogen TT; in
terms of this effect, the wild-type strain was much lower
than the asp-introduced strain, but higher than the asp-
disrupted strain (Fig. 5a). Although the asp-disrupted strain
did not secrete ASP (Fig. 4), its culture supernatant pro-
longed ﬁbrinogen TT signiﬁcantly (Fig. 5a), apparently
indicating the effect of non-serine-type ﬁbrinogenolytic
protease(s) in the supernatant (Fig. 4). The supernatant of
the vector-introduced T94 strain, secreting neither ASP nor
metalloprotease (Table 1), also had a signiﬁcant ﬁbrinogen-
olytic activity lower than that of the wild strain (Fig. 5a).
The culture supernatant of the asp-introduced strain pro-
longed human plasma TT the most, followed by that of the
wild-type strain; culture supernatants of the asp-disrupted
and the vector-introduced strains exerted no signiﬁcant
effect on plasma TT (Fig. 5b), consistent with the order of
the serine protease activity for the ASP-speciﬁc substrate
in the supernatants (Fig. 4). Based on the DFP-sensitive
serine protease activity for the ASP-speciﬁc substrate, the
wild-strain culture supernatant was estimated to contain
about 170nM ASP, corresponding to 17nM in the TTassay.
The TT-prolongation effect of the wild-type strain super-
natant (Fig. 5a and b) appeared to be close to that of 17nM
ASP (Fig. 2a and b), and slightly higher, probably because of
the effect of other proteases in the supernatant. Taken
together, ASP likely accounted for most of the ﬁbrinogen
clottability-abrogating activity secreted from the wild
A. sobria and caused impaired plasma clotting.
Discussion
Invading bacteria interact with host components, causing
infectious diseases. Plasma proteins leak from the blood
stream into infected sites through vascular permeability,
enhanced by inﬂammatory responses against infections,
and in sepsis, bacteria ﬂow in the plasma. It is relevant that
the interaction of plasma proteins with bacterial compo-
nents is involved in the pathophysiology of infectious
disease. In fact, the interaction of ASP with human ﬁbrino-
gen resulted in rapid degradation (Fig. 3) and clottability
reduction (Fig. 2a and b) of this clotting factor. The asp-
disrupted strain culture supernatant, deﬁcient in ASP (Fig.
4), lacked most of the TT prolongation activity, whereas
that of the wild-type or the ASP gene-introduced strain
exerted this activity in a serine protease-dependent manner
(Fig. 5a and b), indicating a major contribution of ASP
to the ﬁbrinogenolytic activity released from A. sobria.
Furthermore, the ﬁnding that the culture supernatant of
the A. sobria wild-type strain impaired plasma clottability
(Fig. 5b) suggests the induction of hemorrhagic tendencies
due to ﬁbrinogen degradation by ASP secreted from this
pathogen in sepsis. A subtilisin-like serine protease from
group B Streptococcus has been reported to cleave human
ﬁbrinogen and the fact that the protease-gene-null mutant
was 10 times less virulent in a neonatal rat sepsis model of
group B Streptococcus infection indicates that this ﬁbrino-
gen-cleaving proteaseisan important virulencefactorof this
pathogen (Harris et al., 2003). Fibrinogenolysis by ASP is
thought to be a new virulence activity of A. sobria,i n
addition to the kinin-releasing activityassociated withshock
induction (Imamura et al., 2006).
Estimating from the previous results (Imamura et al.,
1995), the result that the ﬁbrinogen TT was prolonged by
ASP at 30nM (Fig. 2b) indicated that more than 80% of the
ﬁbrinogen lost clottability after a 3-min incubation with
ASP, corresponding to the disappearance of the Aa-chain by
2min (Fig. 3). Therapid cleavageof the ﬁbrinogen Aa-chain
by ASP (Fig. 3), like the physiological ﬁbrinogenolytic
protease plasmin (Pizzo et al., 1972), indicates ASP’s
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40 T. Imamura et al.preference for this chain as a substrate. ASP is a subtilisin-
like protease that prefers paired Lys and/or Arg residues and
cleaves the peptide bonds at the carboxy-terminal side of the
paired basic amino acid residues (Kobayashi et al., 2006).
That such paired residues are fewer in the g-chain (two
pairs) than in the Aa- and the Bb-chains (seven pairs)
(Halkier, 1991) may be associated with the g-chain being
relatively resistant to ASP, but is not consistent with ASP
degrading the Aa-chain faster than the Bb-chain (Fig. 3).
The ability of ASP to cleave the peptide bonds at the
carboxy-terminal side of Arg residues (Imamura et al.,
2006; Kobayashi et al., 2006) and differences in the three-
dimensional structure between the Aa- and Bb-chains may
explain the ASP cleavage preference for the Aa-chain (Fig. 3).
Although ASP is the major ﬁbrinogenolytic protease in
the culture supernatant of the wild-type A. sobria strain,
signiﬁcant ﬁbrinogenolytic activity remains in the asp-
disrupted strain culture supernatant (Fig. 5a), even though
it contains negligible serine protease activity (Fig. 4). Aero-
monas species produce metalloproteases (Toma et al., 1999),
and the culture supernatant of the vector-introduced T94
strain, which does not produce ASP and metalloprotease
(Khan et al., 2007), also contained DFP-resistant caseinoly-
tic activity comparable to that of the asp-disrupted strain
(Fig. 4). Nonserine proteases are likely involved in the
residual ﬁbrinogenolytic activity in the culture supernatant
of the asp-disrupted strain. However, the result that culture
supernatants of the asp-disrupted or the vector-introduced
T94 strains exerted no signiﬁcant effect on plasma TT
(Fig. 5b) suggested a marginal effect of other proteases on
the plasma clottability. Taken together, ﬁbrinogen cleavage
at the Aa-chain by ASP appears to be primarily responsible
for plasma clottability abrogation by A. sobria.
This study demonstrates that ASP, secreted by A. sobria at
the infection sites or in the circulation, can cause ﬁbrinogen
degradation as a major executioner, possibly contributing to
induction of hemorrhagic tendencies in sepsis. Accordingly,
ASP is considered to be an important virulence factor; thus,
it may be a therapeutic target for A. sobria infection diseases
and ASP-speciﬁc inhibitors may be useful as drugs. Aero-
monas species other than A. sobria also secrete subtilisin-
type serine proteases (64kDa) (Coleman & Whitby, 1993),
and their infections also cause sepsis (Janda & Brenden,
1987; Janda et al., 1994). Thus, such inhibitors may be
widely beneﬁcial in the treatment of diseases caused by
Aeromonas infections.
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